Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
Violin. Yes it's very vulnerable. We need good data soon and some new deals.
It's always been an unloved stock, no PI interests and no trader interest. Missed deadlines and poor communication in the past hasn't helped but we have new people on board now who can change the Company image/culture/business practices.
Good clear RNS. All Conference info in one place. Well done Scancell.
What type of deal are you meaning Dragon? A new mAbs deal or a deal for the Company or part of the pipeline?
All I actually came on to say was that the 2nd Genmab milestone will be for a small amount and the 3rd milestone payment is many years away. Potential new deals we don't know.
The irony is that we are all here speculating.
Yes Ruck, Lindy said the 2nd milestone payment would be somewhat similar to the first hence my thought that it won't do anything much for the SP. (It may not cover staff salaries for the year so I don't think it would stave off another fund raise. We really need to make more sales at better value. The reason for Mandeep's appointment )
I'm hoping for way more than you suggest in a shorter time frame if I'm being honest. If it goes for only a pound then that surely suggests it is a waste of time investing in life saving drugs in the UK. (removing all ethical reasons) Statistically, Premium Bonds would have had a better return for LTH's.
Anyway, I don't want to post more that will come across as being negative, I really just wanted to clear up the misconception that a Genmab payment was likely to do much in the near term.
Perhaps you are right BOjo, it just seemed like a lot of shares to give up. PI's lost a third of our stake in Scancell overnight. Let us hope Mandeep is working on something as we speak.(she will be responsible for first instalment on any new mAbs deals so perhaps her upfront valuation is much higher now than as was Genmab) I still have many other fears so hopefully data of some sort comes sooner rather than later.
TF, Yes, the data is key.
Management need to step up, keep us informed and give reassurances that we are not going to be sold short if any offer comes in.
Private investors have been hammered, 800m shares to 1.2 billion for what seems to be a fairly small sum. It was one heck of a dilution. I'm sure many will disagree though. I'm just trying to provide balance here and want this Company to succeed as much anyone, but so far our new appointments haven't delivered anything tangible yet.
Again, I'm sure you agree, there is no magical milestone payment of worth for the first mAb any time soon.
Ray/Bojo. Lindy said at the AGM that meaningful milestone payments/royalties from Genmab are stage 3 and perhaps 5 years down the road. So it's fair to assume any 2nd milestone payment will be similar to the first, e.g. not going to add anything to the share price. Genmab got one heck of a good deal. Scancell made this clear to the market at the AGM.
Violin is correct, funded till 25 we heard etc etc then a massive dilution just days after.
I pray the next mAbs deal is at a value 10 times the Genmab deal. That way, the market can really value that part of the business.
We urgently need some good news/data to get us out of the doldrums.
Thanks for posting that Chelsea.
Good post Chester.
EE. I hope the irony of your last post is not lost on the 4 members who ticked up your post as we sit here a decade on at a very massively diluted 11p. Just as well we have been paying close attention to those unknown unknowns over the years.
FWIW I totally agree with your previous post regarding London v NY.
No, nothing odd about it WTP. it's just investor fatigue and the fact Scancell haven't delivered yet.
After being uber positive for the previous 10 years I think it's only fair that tough questions are asked. If you are happy with a massive dilution which will ultimately reduce your cash out price and a decimated share price then that's fine.
Scancell is a Company who will either succeed or fade. I've bet long term it will succeed but it doesn't mean that I have to agree with everything written on here. My question to everyone on the board was 'what do you think may move the share price short term?' No one really could suggest anything other than 'wait for data' and 'perhaps something out of the blue"as I myself suggested.
We all see things differently, I still have huge hope for the science.
If you have a handy link at hand I will re listen to the presentation, I certainly have never intended to mislead anyone, I'm a long term holder who invested for both ethical and financial gains. I continue to hold but obviously interpreted the presentation differently to you and others. I took the trial future data updates as being very positive and the information and 'value' of mAbs as being negative for 2024. (In the sense that one deal at a similar value to the Genmab deal will not move the share price) Maybe you think a 6 million Euro deal will move it?
M.
Thanks Ray.
Thanks, Appreciate Berm.
You couldn't resist .
Rather than sell up own a whim as you immaturely suggest, I'll contact Scancell.
Put me on ignore.
WTP. We know there is demand, Lindy said so last week. We also know she expects one deal this year. She said so last week.
I'm specifically asking if any other competitor now has the capability to produce such antibodies and whether there is anything in print suggesting a payment from Genmab in the near term.
If you don't know then just ignore this post, put me on ignore rather than resorting to 'just sell up'.
Cleaner. I've read all your posts.
You haven't really answered either question I asked with respect.
WTP, Thanks for the reply. I'll take that as a 'you can't answer either question either'.
Back in early 2023, Lindy quoted ' We remain one of only a few companies worldwide that has the capability to produce high affinity, humanised anti-glycan antibodies and continue to evaluate options and potential agreements for the Company's GlyMab® antibodies in order to provide further third-party validation, develop the business and generate revenues.'
Do any of our scientific contributors or researchers know if this is still the case or are others now developing in this space?
Also, I noticed on the other board (I don't look in there as often as I should) that Marcus suggested a milestone payment on his potential upcoming news list. Does anyone have a quote or information suggesting this is possible even this year as I can't find anything that suggests that it is near?
Thanks in advance.
Thanks DeAar, Emptyend.
So nothing that would increase the SP near term then. So we wait for trial data.
Empty.
Any thoughts on what you think exclusivity is worth in Pounds?